Parechovirus A3 (PeV-A3)-associated myalgia/myositis occurs irrespective of its genetic cluster: a longitudinal molecular epidemiology of PeV-A3 in Yamagata, Japan between 2003 and 2016
No longitudinal molecular epidemiology of parechovirus A3 (PeV-A3) over a decade is available and PeV-A3-associated myalgia/myositis has been reported only in Japan. Thus, we aimed to clarify the longitudinal molecular epidemiology of PeV-A3 with a major focus on the strains detected from PeV-A3-associated myalgia/myositis cases. We performed sequence and phylogenetic analysis for the VP1 region of PeV-A3 strains in Yamagata, Japan, between 2003 and 2016. The phylogenetic analysis indicated that PeV-A3 strains caused PeV-A3-associated myalgia/myositis as well as a variety of infectious diseases, ranging from mild to severe, in subjects ranging from neonates to adults, irrespective of genetic cluster or variations. PeV-A3 strains are causative agents of a variety of human diseases, irrespective of their genetic cluster. Furthermore, we consider that PeV-A3-associated myalgia/myositis may occur, not only in Japan, but also in other countries, as closely related PeV-A3 strains have been circulating around the world.
RomeroJR, ModlinJF. Human parechoviruses. In BlaserMJ. (editor) Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th ed. Philadelphia: Saunders Elsvier; 2015 pp. 2091–2094
ItoM, YamashitaT, TsuzukiH, TakedaN, SakaeK. Isolation and identification of a novel human parechovirus. J Gen Virol2004; 85:391–398 [View Article][PubMed]
ItoM, YamashitaT, TsuzukiH, KabashimaY, HasegawaA et al. Detection of human parechoviruses from clinical stool samples in Aichi, Japan. J Clin Microbiol2010; 48:2683–2688 [View Article][PubMed]
van der SandenS, de BruinE, VennemaH, SwaninkC, KoopmansM et al. Prevalence of human parechovirus in the Netherlands in 2000 to 2007. J Clin Microbiol2008; 46:2884–2889 [View Article][PubMed]
HarvalaH, RobertsonI, ChieochansinT, Mcwilliam LeitchEC, TempletonK et al. Specific association of human parechovirus type 3 with sepsis and fever in young infants, as identified by direct typing of cerebrospinal fluid samples. J Infect Dis2009; 199:1753–1760 [View Article][PubMed]
AizawaY, SuzukiY, WatanabeK, OishiT, SaitohA. Clinical utility of serum samples for human parechovirus type 3 infection in neonates and young infants: The 2014 epidemic in Japan. J Infect2016; 72:223–232 [View Article][PubMed]
SchuffeneckerI, JavouheyE, GilletY, KugenerB, BillaudG et al. Human parechovirus infections, Lyon, France, 2008-10: evidence for severe cases. J Clin Virol2012; 54:337–341 [View Article][PubMed]
NelsonTM, VuillerminP, HodgeJ, DruceJ, WilliamsDT et al. An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3. Sci Rep2017; 7:44423 [View Article][PubMed]
SharpJ, HarrisonCJ, PuckettK, SelvarajuSB, PenarandaS et al. Characteristics of young infants in whom human parechovirus, enterovirus or neither were detected in cerebrospinal fluid during sepsis evaluations. Pediatr Infect Dis J2013; 32:213–216 [View Article][PubMed]
PhamNT, TrinhQD, KhamrinP, ManeekarnN, ShimizuH et al. Diversity of human parechoviruses isolated from stool samples collected from Thai children with acute gastroenteritis. J Clin Microbiol2010; 48:115–119 [View Article][PubMed]
HuangYP, HsiehJY, WuHS, YangJY. Molecular and epidemiological study of human parechovirus infections in Taiwan, 2007-2012. J Microbiol Immunol Infect2016; 49:321–328 [View Article][PubMed]
TanakaS, AokiY, MatobaY, YahagiK, ItagakiT et al. Seroepidemiology of human parechovirus types 1, 3, and 6 in Yamagata, Japan, in 2014. Microbiol Immunol2016; 60:854–858 [View Article][PubMed]
MizutaK, YamakawaT, NagasawaH, ItagakiT, KatsushimaF et al. Epidemic myalgia associated with human parechovirus type 3 infection among adults occurs during an outbreak among children: findings from Yamagata, Japan, in 2011. J Clin Virol2013; 58:188–193 [View Article][PubMed]
MizutaK, YamakawaT, KurokawaK, ChikaokaS, ShimizuY et al. Epidemic myalgia and myositis associated with human parechovirus type 3 infections occur not only in adults but also in children: findings in Yamagata, Japan, 2014. Epidemiol Infect2016; 144:1286–1290 [View Article][PubMed]
YamakawaT, MizutaK, KurokawaK, NagasawaH, YamadaT et al. Clinical characteristics of 17 adult patients with epidemic myalgia associated with human parechovirus type 3 infection. Rinsho Shinkeigaku2017; 57:485–491 [View Article][PubMed]
YamamotoSP, KaidaA, NaitoT, HosakaT, MiyazatoY et al. Human parechovirus infections and child myositis cases associated with genotype 3 in Osaka City, Japan, 2014. J Med Microbiol2015; 64:1415–1424 [View Article][PubMed]
ShinomotoM, KawasakiT, SugaharaT, NakataK, KotaniT et al. Yoshitake H, Yuasa K, Saeki M, Fujiwara Y. First report of human parechovirus type 3 infection in a pregnant woman. Int J Infect Dis2017; 59:22–24
TanakaS, KunishiY, OtaM, OnoA, KannoN et al. Kurakami Y, Yanagibashi T, Matsubayashi M, Hao Y, Iwabuchi K, Oshita F, Yoshie K, Kato Y. Severe human parechovirus type 3 infection in adults associated with gastroenteritis in their children. Infect Dis2017; 49:772–774
National Institute of Infectious Diseases and Tuberculosis and Infectious Diseases Control Division, Ministry of Health, Labour and Welfare Weekly detection of human parechovirus type 3 in 2013 and 2014, Japan. Infectious Agents Surveillance Reporthttp://www.nih.go.jp/niid/images/iasr/arc/ot/2014/data2014.84j.pdf Accessed 25th February 2016
Parechovirus A3 (PeV-A3)-associated myalgia/myositis occurs irrespective of its genetic cluster: a longitudinal molecular epidemiology of PeV-A3 in Yamagata, Japan between 2003 and 2016